An adherence programme to support treatment of people with mental health conditions helped spur Janssen to success at last night’s Pharmaceutical Market Excellence Awards (PMEA) in London.
Janssen picked up the prestigious Accenture Award for PMEA Company of the Year at the event, which recognises responsible marketing and business practice in the pharma industry.
The Maintaining Adherence Programme, which was supported by Havas Lynx, claimed victory in the inVentiv Health Communications Award for Excellence in Healthcare Collaboration and Partnerships category and the KnowledgePoint360 Special Award for Innovation.
Commenting on Janssen’s year, PMEA judges described the company as “an organisation driven by passion” which had a strong leader in the form of managing director Cesar Rodriguez.
Of special note was the company’s approach to its employees and its success in market access in the UK.
“People enjoy working at Janssen – it was rated the top pharma company in The Sunday Times’ Best Companies To Work For in 2012,” said the judges. “And the 100 per cent success rate Janssen have with NICE speaks for itself, a massive achievement in access for patients.”
Regarding the award-winning Maintaining Adherence Programme, judges praised Janssen’s collaborative efforts with the South Essex Partnership University (SEPT) that used digital methods to improve medicines adherence for patients with schizophrenia, bipolar and affective disorders.
“Through a well-executed, multi-faceted, multi-channel, patient programme implemented alongside the NHS, Janssen used an innovative approach which improved adherence, reduced exacerbations and admissions and produced real outcomes for the community,” said the judges.
Run by PMLiVE’s publisher the PMGroup, the PMEA programme is specifically designed to recognise and commend excellence, best practice and innovation in local, European and international healthcare markets.